Market Overview

Ischemia-Reperfusion Injury Drug Development Pipeline Analysis Report 2018 -


The "2018
Ischemia-Reperfusion Injury Drug Development Pipeline Analysis Report-
Companies, Drugs, Clinical Trials, Latest Developments in
Ischemia-Reperfusion Injury Market"
report has been added to's

Cardiac ischemia-reperfusion injury (IRI) is a heart related condition
in which blood supply is restored to the tissue after some period of
ischemia or absence of oxygen supply. The new supply causes additional
complications such as inflammation, innate immunity, and oxidative
stress instead of restoring regular function.

To assist researchers, investors and business development managers, the
publisher has come up with a comprehensive report on
Ischemia-Reperfusion Injury pipeline. The report provides insights into
different therapeutic candidates in preclinical, research, discovery,
NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs
under development directly and through combination with other drugs are
also included.

Current status, developmental phase, participating companies and
entities, recent developments, orphan drug/ fast track/ other
designations, drug class are provided for each Ischemia-Reperfusion
Injury pipeline product. Mechanism of Action and the target area of the
pipeline product are also provided. Further, clinical and preclinical
trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key
trends in Ischemia-Reperfusion Injury pipeline studies. The products
under development are categorized according to their development phase,
mechanism and company to provide detailed insights into the type of
drugs being developed and the stages of development.

Companies Mentioned

  • Angion Biomedica Corp
  • Armaron Bio Pty Ltd
  • BioMedCore Inc
  • Bolder Biotechnology Inc
  • Catalyst Biosciences Inc
  • Celdara Medical LLC
  • CFM Pharma Holding BV
  • Corline Biomedical AB
  • Faraday Pharmaceuticals
  • Glucox Biotech AB
  • Ischemix Inc
  • MallInckrodt Plc
  • Miragen Therapeutics Inc
  • NovelMed Therapeutics Inc
  • Opsona Therapeutics Ltd
  • Pharming Group NV
  • Prolong Pharmaceuticals LLC
  • Prothix BV
  • Radikal Therapeutics Inc
  • SBI Pharmaceuticals Co Ltd
  • TheraSource LLC
  • TRIM-edicine Inc
  • X-In8 Biologicals Corp

Key Topics Covered:

1 Table of Contents

2 Ischemia-Reperfusion Injury Pipeline Analysis

3 Ischemia-Reperfusion Injury- Company Wise Pipeline Analysis

4 Ischemia-Reperfusion Injury R&D Pipeline Snapshots

5 Recent Developments in Ischemia-Reperfusion Injury Pipeline

6 Appendix

For more information about this report visit

View Comments and Join the Discussion!